Celltrion CEO faces investigation of share manipulation

Just months after winning European approval for a biosimilar of Remicade, Korea's Celltrion says its CEO--and largest shareholder--faces a formal investigation for stock manipulation. The country's Financial Services Commission has asked prosecutors to step in, reports Bloomberg, possibly complicating the planned sale of Kim Joon Seok's stake in the manufacturer. Rumors had been circulating that AstraZeneca ($AZN) was interested in snagging the stock. Story

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.